Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (CR Sanjiu) is a leading Chinese pharmaceutical company specializing in the research, development, and manufacturing of over-the-counter (OTC) drugs and Traditional Chinese Medicine (TCM). The company is most famous for its 999 brand, which maintains a dominant market share in China for cold and flu remedies, gastrointestinal treatments, and dermatological products. Beyond its consumer health leadership, CR Sanjiu operates a robust prescription drug division focusing on anti-infectives, cardiovascular health, and oncology. As a core subsidiary of the state-owned China Resources Group, the company utilizes an extensive national distribution network and advanced manufacturing facilities. CR Sanjiu is increasingly investing in innovative drug development, including biologics and small molecules, through internal R&D and strategic global partnerships.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on 999 Brand.